Advertisement
ResearchIn-Press PreviewInflammationVascular biology
Open Access | 10.1172/JCI174135
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Suzuki, T. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Loyde, E. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Chen, S. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Etzrodt, V. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Idowu, T. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by
Clark, A.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by
Saade, M.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Flores, B. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Lu, S. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by
Birrane, G.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by Vemireddy, V. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by
Seeliger, B.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by David, S. in: JCI | PubMed | Google Scholar
1Division of Nephrology, Department of Medicine, University of Texas Southwestern, Dallas, United States of America
2Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
3Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States of America
4Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
5Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
Find articles by
Parikh, S.
in:
JCI
|
PubMed
|
Google Scholar
|
Published March 3, 2025 - More info
Elevated Angiopoietin-2 is associated with diverse inflammatory conditions including sepsis, a leading global cause of mortality. During inflammation, Angiopoietin-2 antagonizes the endothelium-enriched receptor Tie2 to destabilize the vasculature. In other contexts, Angiopoietin-2 stimulates Tie2. The basis for context-dependent antagonism remains incompletely understood. Here we show that inflammation-induced proteolytic cleavage of Angiopoietin-2 converts this ligand from Tie2 agonist to antagonist. Conditioned media from stimulated macrophages induced endothelial Angiopoietin-2 secretion. Unexpectedly, this was associated with reduction of the 75 kDa full-length protein and appearance of new 25 and 50 kDa C-terminal fragments. Peptide sequencing proposed cathepsin K as a candidate protease. Cathepsin K was necessary and sufficient to cleave Angiopoietin-2. Recombinant 25 and 50 kDa Angiopoietin-2 fragments (cANGPT225, cANGPT250) bound and antagonized Tie2. Cathepsin K inhibition with the Phase-3 small molecule inhibitor odanacatib improved survival in distinct murine sepsis models. Full-length Angiopoietin-2 enhanced survival in endotoxemic mice administered odanacatib and, conversely, increased mortality in the drug’s absence. Odanacatib’s benefit was reversed by heterologous cANGPT225. Septic humans accumulated circulating Angiopoietin-2 fragments, which were associated with adverse outcomes. These results identify cathepsin K as a candidate marker of sepsis and a proteolytic mechanism for the conversion of Angiopoietin-2 from Tie2 agonist to antagonist with therapeutic implications for inflammatory conditions associated with Angiopoietin-2 induction.